BBIO
BridgeBio Pharma, Inc. Common Stock
Nasdaq · usd
BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $78.01 (+1.58%) as of 4:09:19 AM EST on Nov 19, 2026, +15.48% over the past month. Market cap is $15.2B, with 7.1 days to cover in short interest.
Stock performance
How BridgeBio Pharma, Inc. Common Stock (BBIO) stock has performed from one day to one year, with its 52-week range.
- 1D
- +1.58%
- 1W
- -1.92%
- 1M
- +15.48%
- YTD
- +1.99%
- 1Y
- +20.72%
- 52-wk range
- $62.50 – $93.42
Key statistics
Today's trading snapshot for BBIO: day range, open, previous close, volume and market cap.
- Day range
- $75.99 – $78.25
- Open
- $76.45
- Prev close
- $76.80
- Volume
- 3.65M
- Market cap
- $15.2B
- Shares out
- 194.8M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for BridgeBio Pharma, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 16.07
- P/B
- -9.14
- P/FCF
- —
- ROE
- 35.6%
- ROA
- -27.4%
- Debt/Equity
- -1.49
- Div yield
- 0.02%
As of Nov 18, 2026
8-K filings
Material corporate events BridgeBio Pharma, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsOct 29, 2026
On October 29, 2026, BridgeBio Pharma, Inc. (the "Company") reported recent business updates and its financial results for the third quarter ended September 30, 2026.
- Regulatory decisionOct 13, 2026
On October 6, 2026, BridgeBio Pharma, Inc. issued a press release titled "BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia."
- Public offeringAug 17, 2026
The Offering was made pursuant to the Company's effective shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus dated July 24, 2026, as supplemented by a prospectus supplement dated August 13, 2026, filed on August 14, 2026. The sale of the Shares is expected to be completed on August 17, 2026.
- Regulatory decisionJul 22, 2026
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1. On July 22, 2026, BridgeBio Pharma, Inc. issued a press release titled 'BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1.'
- Charter amendmentJul 2, 2026
In connection with the issuance of the Preferred Stock, on the Closing Date, the Company filed a Certificate of Designations with the Secretary of State of the State of Delaware, establishing the designations, powers, preferences and rights of the Preferred Stock. The Certificate of Designations became effective upon filing.
BBIO short interest
How heavily BBIO is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.1
- Short interest
- 20.85M
- Avg volume
- 2.95M
As of · reported to FINRA twice monthly.
BBIO news
The latest news and headlines about BridgeBio Pharma, Inc. Common Stock (BBIO).
- Should You Invest $1,000 in BridgeBio Pharma Right Now?positiveThe Motley Fool· Nov 2, 2026
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowpositiveZacks Investment Research· Oct 20, 2026
- Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health RecordspositiveGlobeNewswire Inc.· Oct 11, 2026
- Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1positiveGlobeNewswire Inc.· Oct 11, 2026
- FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingpositiveZacks Investment Research· Oct 7, 2026
Frequently asked questions
What is the BridgeBio Pharma, Inc. Common Stock (BBIO) stock price today?
BridgeBio Pharma, Inc. Common Stock (BBIO) is trading at $78.01 (+1.58% on the day) as of 4:09:19 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is BridgeBio Pharma, Inc. Common Stock?
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene…
What is the short interest in BBIO?
As of Oct 30, 2026, BBIO has 20.85M shares short and 7.1 days to cover.
What exchange is BBIO listed on?
BridgeBio Pharma, Inc. Common Stock (BBIO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of BBIO with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a BBIO analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.